Aslan Pharma Starts Phase I Trial of Lead Molecule in Taiwan

Aslan Pharma, based in Singapore, has begun dosing patients in a Taiwan Phase I trial of its lead compound, ASLAN001, in patients with solid tumors, especially gastric cancer. ASLAN001 is a small molecule, oral pan-HER inhibitor that Aslan in-licensed from Array Biopharma in 2011. The molecule successfully completed a Phase IIa trial as a second-line treatment among a similar patient population in South Korea last year. More details.... Stock Symbol: (NSDQ: ARRY) Share this with colleagues: // //